Secreted klotho and chronic kidney disease.

Abstract

Soluble Klotho (sKl) in the circulation can be generated directly by alterative splicing of the Klotho transcript or the extracellular domain of membrane Klotho can be released from membrane-anchored Klotho on the cell surface. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23), sKl, acts as hormonal factor and plays important roles in anti-aging, anti-oxidation, modulation of ion transport, and Wnt signaling. Emerging evidence reveals that Klotho deficiency is an early biomarker for chronic kidney diseases as well as a pathogenic factor. Klotho deficiency is associated with progression and chronic complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. In multiple experimental models, replacement of sKl, or manipulated up-regulation of endogenous Klotho protect the kidney from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

• Authors: Ming Chang Hu, Makoto Kuro-o, Orson W Moe
• Journal: Advances in experimental medicine and biology (Adv Exp Med Biol) Vol. 728 Pg. 126-57 ( 2012) ISSN: 0065-2598 [Print] United States
• PMID: 22396167 (Publication Type: Journal Article, Review)

Chemical References

• FGF23 protein, human
• Fibroblast Growth Factor-23
• Glucuronidase
• Klotho Proteins

Topics

• Animals
• Chronic Disease
• Disease Progression
• Fibroblast Growth Factor-23
• Glucuronidase (biosynthesis, deficiency, metabolism)
• Humans
• Kidney (metabolism, pathology, physiopathology)
• Kidney Diseases (complications, metabolism, pathology, physiopathology)
• Klotho Proteins